These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 15611064

  • 1. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F, Kentsis A, Osman R, Pan ZQ.
    J Biol Chem; 2005 Mar 04; 280(9):7985-96. PubMed ID: 15611064
    [Abstract] [Full Text] [Related]

  • 2. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.
    J Biol Chem; 2000 Aug 18; 275(33):25733-41. PubMed ID: 10823831
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER.
    Oncogene; 2001 Aug 16; 20(36):5067-74. PubMed ID: 11526493
    [Abstract] [Full Text] [Related]

  • 5. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ.
    Mol Cell Biol; 2002 Mar 16; 22(6):1947-60. PubMed ID: 11865071
    [Abstract] [Full Text] [Related]

  • 6. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha.
    Yuan Y, Hilliard G, Ferguson T, Millhorn DE.
    J Biol Chem; 2003 May 02; 278(18):15911-6. PubMed ID: 12606543
    [Abstract] [Full Text] [Related]

  • 7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH.
    Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720
    [Abstract] [Full Text] [Related]

  • 8. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
    Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ.
    IUBMB Life; 2001 Jul 16; 52(1-2):43-7. PubMed ID: 11795592
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC.
    Cancer Res; 2004 Dec 01; 64(23):8595-603. PubMed ID: 15574766
    [Abstract] [Full Text] [Related]

  • 10. Proline hydroxylation at different sites in hypoxia-inducible factor 1α modulates its interactions with the von Hippel-Lindau tumor suppressor protein.
    Qian H, Zou Y, Tang Y, Gong Y, Qian Z, Wei G, Zhang Q.
    Phys Chem Chem Phys; 2018 Jul 11; 20(27):18756-18765. PubMed ID: 29961792
    [Abstract] [Full Text] [Related]

  • 11. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.
    Hum Mol Genet; 2001 May 01; 10(10):1029-38. PubMed ID: 11331613
    [Abstract] [Full Text] [Related]

  • 12. Regulation of the HIF pathway: enzymatic hydroxylation of a conserved prolyl residue in hypoxia-inducible factor alpha subunits governs capture by the pVHL E3 ubiquitin ligase complex.
    Mole DR, Pugh CW, Ratcliffe PJ, Maxwell PH.
    Adv Enzyme Regul; 2002 May 01; 42():333-47. PubMed ID: 12123724
    [No Abstract] [Full Text] [Related]

  • 13. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 May 01; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

  • 14. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
    Corn PG, McDonald ER, Herman JG, El-Deiry WS.
    Nat Genet; 2003 Nov 01; 35(3):229-37. PubMed ID: 14556007
    [Abstract] [Full Text] [Related]

  • 15. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
    Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY.
    Nature; 2002 Jun 27; 417(6892):975-8. PubMed ID: 12050673
    [Abstract] [Full Text] [Related]

  • 16. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
    Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P, Metzen E.
    Biochem J; 2004 Aug 01; 381(Pt 3):761-7. PubMed ID: 15104534
    [Abstract] [Full Text] [Related]

  • 17. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.
    Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M.
    J Biol Chem; 2003 Mar 28; 278(13):11032-40. PubMed ID: 12538644
    [Abstract] [Full Text] [Related]

  • 18. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
    Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM, Barrett JC.
    J Cell Biochem; 2004 Jun 01; 92(3):491-501. PubMed ID: 15156561
    [Abstract] [Full Text] [Related]

  • 19. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z, Liu S, Guo M, Mao J, Hughson MD.
    Cancer Genet Cytogenet; 2004 Jul 15; 152(2):89-94. PubMed ID: 15262424
    [Abstract] [Full Text] [Related]

  • 20. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER.
    Oncogene; 2005 Jun 30; 24(28):4549-58. PubMed ID: 15824735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.